Odronextamab

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

LymphomaDiffuse Large B-Cell LymphomaFollicular LymphomaLupus NephritisRecurrent Diffuse Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma(dlbcl)Follicular Lymphoma (FL)Lupus Nephritis (LN)

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

1

Odronextamab

Regeneron

Phase 3

52

Zofran

Novartis

Preclinical

23

Norvir

AbbVie

Preclinical

14

PEG-Intron

Merck & Co.

Preclinical

15

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—6

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—7

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

38

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Preclinical

39

Stem Cells

KKang Stem Biotech Co., Ltd.

Preclinical

210

Immune Checkpoint Inhibitor

IImmuneSensor Therapeutics Inc.

Preclinical

1Show 22 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Lymphoma5 trials

A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

Recruiting·UUniversity of Birmingham·Phase 2/3·NCT05991388·210 enrolled

Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T

Recruiting·UUniversity of Washington·Phase 2·NCT06784726·27 enrolled

A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies

Active, not recruiting·Regeneron·Phase 2·NCT03888105·515 enrolled

Show 2 more trials

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

Recruiting·Regeneron·Phase 1·NCT05685173·91 enrolled

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

Recruiting·Regeneron·Phase 3·NCT06230224·216 enrolled

B-cell Malignancies2 trials

Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

Completed·Regeneron·Phase 1·NCT02290951·200 enrolled

A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies

Active, not recruiting·Regeneron·Phase 1·NCT02651662·105 enrolled

Follicular Lymphoma2 trials

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

Recruiting·Regeneron·Phase 3·NCT06149286·470 enrolled

A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

Active, not recruiting·Regeneron·Phase 3·NCT06097364·733 enrolled

MPA1 trial

A Compassionate Use (CU) Program of Odronextamab

Available·Regeneron··NCT05619367

Advanced1 trial

Odronextamab in Low Tumor Volume Advanced FL

Recruiting·GGottfried von Keudell, MD PhD·Phase 2·NCT07128641·35 enrolled

5 more indications

Richter's Transformation1 trial

Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation

Recruiting·—·Phase 1·NCT06735664·23 enrolled

Lupus Nephritis (LN)1 trial

A Dose Escalation Study Investigating Bispecific Antibody Therapy in Patients With Lupus Nephritis

Recruiting·Regeneron·Phase 1·NCT06975787·90 enrolled

Diffuse Large B-cell Lymphoma(DLBCL)1 trial

A Phase 3, Open Label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 × Anti-CD3 Bispecific Antibody, in Combination With CHOP (ODRO-CHOP) Versus Rituximab in Combination With CHOP (R-CHOP) in Previously Untreated Participants With Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3)

Recruiting·Regeneron·Phase 3·NCT06091865·904 enrolled

Recurrent Diffuse Large B-Cell Lymphoma1 trial

A Phase 2 Study of Odronextamab in Relapsed/ Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Before and After Chimeric Antigen Receptor (CAR) T-Cell Therapy

Recruiting·JJoseph Tuscano·Phase 2·NCT06854159·34 enrolled

Follicular Lymphoma (FL)1 trial

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator's Choice in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-1)

Recruiting·Regeneron·Phase 3·NCT06091254·822 enrolled

Details

Drug Info

Related News